These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7579359)

  • 1. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
    Ilaria RL; Van Etten RA
    Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
    Jain SK; Susa M; Keeler ML; Carlesso N; Druker B; Varticovski L
    Blood; 1996 Sep; 88(5):1542-50. PubMed ID: 8781408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion.
    Anderson SM; Mladenovic J
    Blood; 1996 Jan; 87(1):238-44. PubMed ID: 8547647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
    Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
    Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
    Bhat A; Johnson KJ; Oda T; Corbin AS; Druker BJ
    J Biol Chem; 1998 Nov; 273(48):32360-8. PubMed ID: 9822717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.
    Goga A; McLaughlin J; Afar DE; Saffran DC; Witte ON
    Cell; 1995 Sep; 82(6):981-8. PubMed ID: 7553858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.
    Seo JH; Wood LJ; Agarwal A; O'Hare T; Elsea CR; Griswold IJ; Deininger MW; Imamoto A; Druker BJ
    Cancer Res; 2010 Sep; 70(18):7325-35. PubMed ID: 20807813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway.
    Tauchi T; Yoshimura A; Ohyashiki K
    Exp Hematol; 2001 Mar; 29(3):356-61. PubMed ID: 11274764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
    Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
    Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
    Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
    Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.
    Odai H; Sasaki K; Iwamatsu A; Nakamoto T; Ueno H; Yamagata T; Mitani K; Yazaki Y; Hirai H
    Blood; 1997 Apr; 89(8):2745-56. PubMed ID: 9108392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.
    Chalandon Y; Jiang X; Loutet S; Eaves AC; Eaves CJ
    Leukemia; 2004 May; 18(5):1006-12. PubMed ID: 15014528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
    J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of wild-type BCR/ABL tyrosine kinase in hematopoietic cells by mild hyperthermia.
    Jain SK; de Aos I; Inai Y; Liu F; Varticovski L
    Leukemia; 2000 May; 14(5):845-52. PubMed ID: 10803516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein.
    Okuda K; D'Andrea A; Van Etten RA; Griffin JD
    Blood; 1998 Nov; 92(10):3848-56. PubMed ID: 9808578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
    Meyn MA; Wilson MB; Abdi FA; Fahey N; Schiavone AP; Wu J; Hochrein JM; Engen JR; Smithgall TE
    J Biol Chem; 2006 Oct; 281(41):30907-16. PubMed ID: 16912036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
    Nosaka T; Kitamura T
    Exp Hematol; 2002 Jul; 30(7):697-702. PubMed ID: 12135666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.